Early Development Asset Lead

Ipsen; Greater London; Hybrid; GBP 120,000 - 180,000; Full time

Job summary

Ipsen recherche un Lead d'actifs de développement précoce (EDAL) pour piloter une ou plusieurs autorisations en phase initiale et diriger l'équipe EDT interfonctionnelle. Le rôle couvre la stratégie intégrée, la translational et les interactions avec les autorités réglementaires.

Le candidat idéal possède 10–15 années d'expérience en développement préclinique à clinique, avec forte expertise en oncologie, IO et/ou ADC, et sait diriger dans un environnement matriciel complexe.

Qualifications

• PhD/MD/PharmD ou équivalent et 10–15 ans d'expérience multidisciplinaire en développement de médicaments.
• Expertise en oncologie; immuno-oncologie et/ou ADCs souhaitée.
• Expérience en dépôts réglementaires (IND/CTA) et interactions avec les autorités.
• Capacité démontrée à diriger des équipes transverses en environnement matriciel.

Responsibilities

• Dirige une ou plusieurs Early Development Asset Teams (EDT).
• Conçoit et gère la stratégie de développement intégrée (préclinique, translational, clinique, réglementaire).
• Présente plans et risques aux organes de gouvernance avec crédibilité scientifique.

Skills

Oncology expertise

Immuno-oncology

ADCs

Translational strategies

Regulatory filings

Leadership in matrix teams

Education

PhD/MD/PharmD ou équivalent

Job description

**Titre :**Early Development Asset Lead**Société:**Ipsen Biopharm Ltd**A propos d'Ipsen:**Ipsen est un groupe biopharmaceutique mondial de taille moyenne, spécialisé dans les médicaments transformateurs dans trois aires thérapeutiques : l'oncologie, les maladies rares et les neurosciences. Forts de près de 100 ans d'expérience en développement, avec des Hubs mondiaux aux États-Unis, en France et au Royaume-Uni, nous focalisons nos efforts là où les besoins médicaux non satisfaits sont importants, grâce à la recherche et à l'innovation.Nos équipes passionnées, présentes dans plus de 40 pays, se concentrent sur l'essentiel et s'efforcent chaque jour d'apporter des médicaments aux patients dans 88 pays. Nous construisons un environnement de travail qui met en avant un leadership centré sur l'humain et favorise une culture de collaboration, d'excellence et d'impact. Au sein d’Ipsen, chaque individu est encouragé à être soi-même, à grandir et à s’épanouir aux côtés du succès de l'entreprise. Rejoignez-nous dans notre démarche vers une croissance durable, en créant un impact réel sur les patients et la société.Pour plus d'informations, visitez notre site web à l'adresse **https://www.ipsen.com** et suivez nos dernières actualités sur **LinkedIn** et **Instagram**.**Description de l'emploi :**Early Development Asset Lead Division / Function: Early Development and Innovation Summary / Purpose of the PositionThe Early Development Asset Lead (EDAL) is a scientific and program leadership role within Ipsen's Early Development and Innovation organization, accountable for integrated development strategy and execution for one or more early-stage therapeutic assets from drug candidate nomination through first-in-human clinical trials. The EDAL leads the Early Development Asset Team (EDT), a cross-functional matrix team spanning clinical, regulatory, CMC, translational, clinical pharmacology, nonclinical safety, and biomarkers, ensuring that each program advances with scientific rigor, strategic clarity, and accountability to portfolio decisions. The EDAL maintains alignment with Therapeutic Area strategy to ensure EDT plans support agreed portfolio priorities, and serves as the scientific champion for assigned programs, articulating project goals, scientific rationale, and clinical line of sight internally and externally. Depending on pipeline needs, the EDAL may represent Early Development in due diligence as the ED lead within a multidisciplinary global team.Main Responsibilities / Job ExpectationsProgram Leadership and Strategy• Leads one or more Early Development Asset Teams.• Owns integrated program strategy across preclinical, translational, clinical, diagnostic, and regulatory activities.• Develops and maintains integrated asset strategy, including target product profile, indication strategy, key development options, competitive context, and evidence required for decision-making.• Ensures Early Development plans deliver against agreed Therapeutic Area strategy and portfolio priorities, with clear evidence-based rationale for stage-gate investment decisions.Cross-Functional Planning and Execution• Integrates input from critical functions and research teams to develop plans that balance scientific risk, timelines, cost, and clinical proof-of-concept potential.• Ensures adequate resources to deliver approved plans, proactively identifies risks, and leads mitigation strategies.Governance and Decision-Making• Presents plans, data, risks, options, and recommendations to governance bodies with scientific credibility, while appropriately leveraging functional expertise.Team Leadership and Communication• Builds high-functioning teams through clear communication of program vision, roles, responsibilities, and decision-making expectations.• Maintains a collaborative, inclusive team environment through influence, coaching, and active stakeholder alignment.Scientific Leadership and External Evaluation• Serves as the scientific champion for assigned programs, articulating project goals, translational hypotheses, and clinical strategy internally and externally.• Contributes to due diligence for in-licensing opportunities and, depending on experience and pipeline need, may coordinate findings and present recommendations to governance.Behaviors and Experience Required Education and Experience• PhD, MD, PharmD, or relevant advanced degree with a minimum of 10-15 years of multidisciplinary drug development experience in the pharmaceutical or biotech industry.• The level offered will be commensurate with scope, independence, and depth of prior early development leadership experience.Scientific and Development Expertise• In-depth understanding of oncology required; experience in immuno-oncology and/or ADCs desirable.• Broad cross-functional drug development knowledge, with experience in more than one functional area, such as nonclinical, translational, regulatory, or clinical development, strongly preferred.• Expertise in small molecules, biologics, and novel modalities preferred.• Experience developing and delivering translational strategies, including biomarker and precision medicine approaches in early-phase clinical trials.• Experience with regulatory filings, including IND/CTA authorship and health authority interactions, required.• Strong understanding of drug development from discovery through life cycle management.Leadership and Matrix Impact• Demonstrated experience leading cross-functional early development teams, with accountability for integrated program strategy and governance-level presentations.• Proven scientific and leadership performance in a matrix environment, as evidenced by pipeline contributions, publications, and/or patent applications.• Demonstrated ability to lead decision-making in a multi-regional, diverse matrix environment.Communication and Stakeholder Management• Proficient in written and oral English; French or another European language is an advantage.• Outstanding communication skills, with the ability to present complex program strategies to senior leadership and governance committees with clarity and scientific credibility.• Ability to build strong relationships with stakeholders across clinical development, clinical operations, translational pharmacology, regulatory, CMC, commercial, medical, and research functions.• Ability to integrate scientific, regulatory, clinical, and commercial perspectives into balanced, portfolio-aligned program strategies.Ways of Working• Strong organizational and project management skills, with the ability to manage multiple priorities and competing timelines.• High emotional intelligence, flexibility, and collaborative mindset, with the ability to seek and evaluate diverse viewpoints. #LI-MM1 #LI-hybrid